• Je něco špatně v tomto záznamu ?

Lymphocytes in the treatment with interferon beta-1 b

Z. Pavelek, O. Vyšata, B. Klímová, C. Andrýs, D. Vokurková, M. Vališ,

. 2017 ; 18 (-) : 29-32. [pub] 20170906

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18033556

BACKGROUND: Multiple sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative disease affecting the central nervous system. One of the basic medications for the treatment of a clinically isolated syndrome (CIS) or relapsing-remitting MS is interferon beta (INFβ). Although the exact mechanism of its effects is unknown, the medication has an anti-inflammatory and immunomodulatory effect. The goal of this study was to determine the characters which are affected in patients treated with INFβ. METHODS: A total of 97 patients (25 males and 72 females) were included into the study. Patients were treated by INFβ 1-b (subcutaneous injection, 250µg, each other day). Clinical evaluations were performed by an attending neurologist. Peripheral blood samples were obtained just prior to treatment and 5 years after INFβ 1-b. Statistical analysis and processing of the obtained data were performed by using a comprehensive statistical software package MATLAB®. RESULTS: A significant decrease of the observed parameters after 5 years' of treatment (significant at the 1% significance level) was found in the absolute and relative CD69 count, absolute cytotoxic/suppressor T lymphocyte count, absolute total leukocyte count, absolute natural killer cells count. A significant decrease of the observed parameters after 5 years' of treatment (significant at the 5% significance level) was found in the absolute lymphocyte count, relative cytotoxic/suppressor T lymphocyte count, relative CD3+CD69+ count and absolute CD8+CD38+ count. CONCLUSION: The treatment with interferon beta reduces clinical exacerbations in multiple sclerosis (MS) through several known immunomodulatory mechanisms. However, the exact mechanism of effect of this medication is not known. This study presents some parameters that were affected by the long-term INFβ treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033556
003      
CZ-PrNML
005      
20181012103951.0
007      
ta
008      
181008s2017 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.msard.2017.08.020 $2 doi
035    __
$a (PubMed)29141817
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Pavelek, Zbyšek $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Hradec Králové, Sokolská 581, 500 05, Czech Republic. Electronic address: zbysekpavelek@email.cz.
245    10
$a Lymphocytes in the treatment with interferon beta-1 b / $c Z. Pavelek, O. Vyšata, B. Klímová, C. Andrýs, D. Vokurková, M. Vališ,
520    9_
$a BACKGROUND: Multiple sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative disease affecting the central nervous system. One of the basic medications for the treatment of a clinically isolated syndrome (CIS) or relapsing-remitting MS is interferon beta (INFβ). Although the exact mechanism of its effects is unknown, the medication has an anti-inflammatory and immunomodulatory effect. The goal of this study was to determine the characters which are affected in patients treated with INFβ. METHODS: A total of 97 patients (25 males and 72 females) were included into the study. Patients were treated by INFβ 1-b (subcutaneous injection, 250µg, each other day). Clinical evaluations were performed by an attending neurologist. Peripheral blood samples were obtained just prior to treatment and 5 years after INFβ 1-b. Statistical analysis and processing of the obtained data were performed by using a comprehensive statistical software package MATLAB®. RESULTS: A significant decrease of the observed parameters after 5 years' of treatment (significant at the 1% significance level) was found in the absolute and relative CD69 count, absolute cytotoxic/suppressor T lymphocyte count, absolute total leukocyte count, absolute natural killer cells count. A significant decrease of the observed parameters after 5 years' of treatment (significant at the 5% significance level) was found in the absolute lymphocyte count, relative cytotoxic/suppressor T lymphocyte count, relative CD3+CD69+ count and absolute CD8+CD38+ count. CONCLUSION: The treatment with interferon beta reduces clinical exacerbations in multiple sclerosis (MS) through several known immunomodulatory mechanisms. However, the exact mechanism of effect of this medication is not known. This study presents some parameters that were affected by the long-term INFβ treatment.
650    _2
$a adjuvancia imunologická $x terapeutické užití $7 D000276
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a injekce subkutánní $7 D007279
650    _2
$a interferon beta 1b $x terapeutické užití $7 D000068576
650    _2
$a počet lymfocytů $7 D018655
650    _2
$a lymfocyty $x účinky léků $x patologie $7 D008214
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a roztroušená skleróza $x krev $x farmakoterapie $x imunologie $x patologie $7 D009103
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vyšata, Oldřich $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Hradec Králové, Sokolská 581, 500 05, Czech Republic.
700    1_
$a Klímová, Blanka $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Hradec Králové, Sokolská 581, 500 05, Czech Republic.
700    1_
$a Andrýs, Ctirad $u Department of Clinical Immunology and Allergology, University Hospital Hradec Králové, Hradec Králové, Sokolská 581, 500 05, Czech Republic.
700    1_
$a Vokurková, Doris $u Department of Clinical Immunology and Allergology, University Hospital Hradec Králové, Hradec Králové, Sokolská 581, 500 05, Czech Republic.
700    1_
$a Vališ, Martin $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Hradec Králové, Sokolská 581, 500 05, Czech Republic.
773    0_
$w MED00188780 $t Multiple sclerosis and related disorders $x 2211-0356 $g Roč. 18, č. - (2017), s. 29-32
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29141817 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181012104443 $b ABA008
999    __
$a ok $b bmc $g 1339497 $s 1030550
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 18 $c - $d 29-32 $e 20170906 $i 2211-0356 $m Multiple sclerosis and related disorders $n Mult Scler Relat Disord $x MED00188780
LZP    __
$a Pubmed-20181008

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...